Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1946 of 5804
-
Exercise as medicine: new trial tests workouts for heart condition
Symptom relief Recruiting nowThe EXCITE-HCM study is a randomized, controlled, blinded clinical trial designed to evaluate the effect of moderate intensity exercise training versus usual physicial activity on the improvement of HCM-related symptoms and cardiac function. About 70 participants will be recruite…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
Which bariatric surgery wins? new trial pits SASI bypass against sleeve gastrectomy
Disease control Recruiting nowThis study will compare two bariatric surgical interventions in terms of weight loss, gastroesophageal reflux, and effects on obesity-related comorbid conditions in morbidly obese patients.
Phase: NA • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Brain tumor samples used to tailor drug cocktails in recurrent glioma trial
Knowledge-focused Recruiting nowThis is an interventional, non-randomized, single site study. Brain tumor samples will be collected from patients for organoids generation and subject to panel drugs screening and QPOP analysis to derive the optimal drug combinations for treatment at the time of first high grade …
Phase: NA • Sponsor: National University Hospital, Singapore • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Could a new Once-Daily pill keep HIV in check? major trial underway
Disease control OngoingThe primary objectives of this study are to evaluate the antiretroviral activity of a switch to Doravirine/Islatravir (DOR/ISL) compared with continued Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) at Week 48; and to evaluate the safety and tolerability of a switc…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
HIV treatment showdown: could simpler drug regimens reduce inflammation?
Knowledge-focused OngoingHIV-infected patients develop comorbidities earlier than the general population. Immune activation with the secretion of pro-inflammatory cytokines would play a major role in the occurrence of these comorbidities. Numerous factors, called risk factors, already identified in the g…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Experimental combo aims to boost leukemia remission
Disease control Recruiting nowThe purpose of the study is to determine the safety of combining the drugs gemtuzumab ozogamicin (GO) with CPX-351 in order to treat the disease, as well as to find the maximum tolerated dose level and recommended Phase 2 dose level of GO with a fixed dose of CPX-351.
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Heart rhythm mystery: 750-Patient study targets AF recurrence after ablation
Knowledge-focused Recruiting nowAtrial fibrillation ablation is the most common intervention performed worldwide. Up to 20 to 45% of patients show recurrence of AF within 12 month after catheter ablation, however its determinant are incompletely understood. The aim of the PROSPECT-AF study is to assess the pre…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Weekly shot may replace daily growth hormone for turner syndrome kids
Disease control OngoingA 104 week dose finding open label trial followed by an optional 78 week open label extension of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus daily somatropin product in prepubertal individuals with Turner syndrome. Approximately 48 ind…
Phase: PHASE2 • Sponsor: Ascendis Pharma Endocrinology Division A/S • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New Clot-Busting device shows promise for lung blockages
Disease control CompletedThe FLARE-FT2 confirmatory study is a prospective, single-arm, multicenter study of the FlowTriever2 Catheter for mechanical thrombectomy of pulmonary embolism (PE).
Phase: NA • Sponsor: Inari Medical • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New brain aneurysm stent shows promise in clinical trial
Disease control CompletedThe purpose of this study is to assess the efficacy and safety of Self-expanding Intracranial Stent (Tonbridge), by comparing the data obtained from Self-expanding Intracranial Stent (Zhuhai Tonbridge Medical Tech. Co., Ltd.) and LVIS/LVIS Jr. (MicroVention Europe SARL) for endov…
Phase: NA • Sponsor: Ton-Bridge Medical Tech. Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Can doctors help families unlock Life-Saving genetic secrets?
Knowledge-focused Recruiting nowThis clinical trial tests whether provider-mediated communication of genetic testing results to at-risk relatives of cancer patients can help improve genetic counseling and testing rates. Approximately 15% of people with cancer have an inherited form of cancer due to changes in a…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Experimental HIV vaccine shows promise in early safety trial
Disease control CompletedThe clinical trial is a dose-escalation, randomized, double-blind, placebo-controlled phase I study at a single center to evaluate the safety, tolerability and immunogenicity of HIV Therapeutic DNA Vaccine, ICVAX, in clinically stable HIV patients under ART treatment.
Phase: PHASE1 • Sponsor: Immuno Cure Holding (HK) Limited • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Buddy system tested to keep HIV patients healthy and in care
Disease control Recruiting nowThe goal of this Hybrid Type I effectiveness-implementation trial is to test an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among people living with HIV aged 18-49.
Phase: NA • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Doctor training could be key to better diabetes control
Disease control CompletedThe purpose of this study is to conduct a prospective, multicenter, cluster randomized control study, to evaluate the improvement for T2DM treatment ability in Chinese endocrinologists after 1-week intensive experiential diabetes management training in Ruijin Hospital.
Phase: NA • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Yoga vs. therapy: which works better for depression?
Symptom relief CompletedThis is a parallel group study design. The investigators propose to compare an online, synchronous group-based yoga intervention developed for individuals with depression to an online, synchronous individualized, evidence-based behavioral therapy for depression, or Brief Behavior…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug JS015 takes first steps against advanced solid tumors
Disease control CompletedThis is a Phase I open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity and antitumor activity of JS015 in patients with advanced solid tumors. The Recommended dose for phase II trial (RP2D) was determined based on the safety, p…
Phase: PHASE1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Could a cheaper copy of a key chemo drug work just as well?
Disease control CompletedTo characterize the pharmacokinetic profile of pegylated liposomal doxorubicin formulations, a multicenter, randomized, two-period crossover study was conducted in 74 patients with advanced ovarian cancer or metastatic breast cancer. Blood samples were collected up to 336 hours p…
Phase: PHASE1 • Sponsor: Zodiac Produtos Farmaceuticos S.A. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Heart shock therapy put to the test: Placebo-Controlled trial reveals true impact on daily life
Symptom relief Recruiting nowAtrial fibrillation (AF) is a type of irregular heart rhythm due to electrical signal disturbances of the heart. It is a very common arrhythmia and the risk of developing AF increases with age and with other risk factors such as diabetes, high blood pressure, and underlying heart…
Phase: NA • Sponsor: Ottawa Heart Institute Research Corporation • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Blood thinner users: how safe is a 24-Hour hospital stay after a mild head bump?
Knowledge-focused OngoingAs a low quality, weak recommendation, it is part of the Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults, that patient with a GCS of 14-15 and anticoagulation therapy and a normal CT should be admitted for observation for at le…
Sponsor: Bispebjerg Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
New study tests Long-Term safety of Cholesterol-Lowering injection for kids
Disease control Recruiting nowThe purpose of this open-label, single arm, multicenter extension study is to evaluate the long-term safety and tolerability of inclisiran in participants with HeFH or HoFH who have completed the ORION-16 (CKJX839C12301), ORION-13 (CKJX839C12302), ORION-20 (CKJX839C12303) or ORIO…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC